Mar. 12, 2022
ASP5878
oral FGFR inhibitor Ph. I candidate for solid tumors opt. from previously disclosed lead Bioorg. Med. Chem. Astellas Pharma Inc.
oral FGFR inhibitor Ph. I candidate for solid tumors opt. from previously disclosed lead Bioorg. Med. Chem. Astellas Pharma Inc.